Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?

References

• Miller G. Is pharma running out of brainy ideas? Science. 2010;329:502–504.
   PubMed Web of Science ®Google Scholar
• Insel T. The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395–397.
   PubMed Web of Science ®Google Scholar
• Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59:216–223.
   PubMed Web of Science ®Google Scholar
• Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165:617–620.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73:675–684.
   PubMed Web of Science ®Google Scholar
• Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15–27.
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2(3 Pt 2):249–255.
   PubMed Web of Science ®Google Scholar
• Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006;163:1179–1186.
   PubMed Web of Science ®Google Scholar
• Grunze H, Kotlik E, Costa R, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord. 2015;174:70–82.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Gueorquieva R, Brandt C, et al. A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder. Neuropsychopharmacol. 2017 May 29. DOI:10.1038/npp.2017.106. [Epub ahead of print].
   Google Scholar
• Smith EG, Deligiannidis KM, Ulbricht CM, et al. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74:966–973.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Johnson MR, Khan A, et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacol. 2016 Nov 2. [Epub ahead of print]. DOI:10.1038/npp.2016.224
   Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1–3):239–243.
   PubMed Web of Science ®Google Scholar
• Sun L, Li Q, Li Q, et al. Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys. Addict Biol. 2014;19:185–194.
   PubMed Web of Science ®Google Scholar
• Huang CC, Wei IH, Huang CL, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74:734–741.
   PubMed Web of Science ®Google Scholar
• Sleigh J, Harvey M, Voss L, et al. Ketamine - more mechanisms of action than just NMDA receptor blockade. Trends Anesth Critical Care. 2014;4(2–3):76–81.
   Google Scholar
• Jukić MM, Opel N, Ström J, et al. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Mol Psychiatry. 2016 Nov 29. [Epub ahead of print]. DOI:10.1038/mp.2016.204
   PubMed Web of Science ®Google Scholar
• De Leon J. Pharmacogenetic tests in psychiatry: from fear to failure to hype. J Clin Psychopharmacol. 2016;36:299–304.
   PubMed Web of Science ®Google Scholar
• Avorn J. The $2.6 billion pill - methodologic and policy considerations. N Engl J Med. 2015;372:1877–1879.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Hwang TJ, Franklin JM. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov. 2015;14:815–816.
   PubMed Web of Science ®Google Scholar
• Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can Phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166:599–607.
   PubMed Web of Science ®Google Scholar
• Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009;99(1–3):248–260.
   PubMed Web of Science ®Google Scholar
• Bosker FJ, Hartman CA, Nolte IM, et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry. 2011;16:516–532.
   PubMed Web of Science ®Google Scholar
• Power RA, Tansey KE, Buttenschøn HN, et al. Genome-wide association for major depression through age at onset stratification: major depressive disorder working group of the psychiatric genomics consortium. Biol Psychiatry. 2017;81:325–335.
   PubMed Web of Science ®Google Scholar
• Luo X, Stavrakakis N, Pennix BW, et al. Does refining the phenotype improve replication rates? A review and replication of candidate gene studies on major depressive disorder and chronic major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2016;171B:215–236.
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office- based psychistry. Arch Gen Psychiatry. 2010;67:26–36.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168:689–701.
   PubMed Web of Science ®Google Scholar
• Howland RH. Serendipity and psychopharmacology. J Psychosoc Nurs Ment Health Serv. 2010;48:9–12.
   Google Scholar
• Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: A STAR*D report. Am J Psychiatry. 2007;164(8):1189–1197.
   PubMed Web of Science ®Google Scholar
• Lewis-Fernández R, Rotheram-Borus MJ, Betts VT, et al. Rethinking funding priorities in mental health research. Br J Psychiatry. 2016;208:507–509.
   PubMed Web of Science ®Google Scholar
• Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171:1278–1286.
   PubMed Web of Science ®Google Scholar
• Van Dam NT, O’Connor D, Marcelle ET, et al. Data-driven phenotypic categorization for neurobiological analyses: beyond DSM-5 labels. Biol Psychiatry. 2017;81:484–494.
   PubMed Web of Science ®Google Scholar
• Shin C, Han C, Pae CU, et al. Precision medicine for psychopharmacology: a general introduction. Expert Rev Neurother. 2016;16:831–839.
   PubMed Web of Science ®Google Scholar